140,000 is in-line with the stats I posted the oth

140,000 is in-line with the stats I posted the other day. RP stayed that CCR5 was over expressed in approximately 50% of colon cancer (along with breast, prostate and pancreatic and other metastatic cancers), so I believe that all of these over expressed CCR5 cancers would be the target patients for leronlimab (pending positive clinical results).

Please do your own due diligence. All my posts and comments are not to be considered investment advice.